Shares of vTv Therapeutics Inc. (NASDAQ:VTVT) dropped 5.7% on Thursday . The stock traded as low as $5.28 and last traded at $5.33, with a volume of 67,579 shares traded. The stock had previously closed at $5.65.

VTVT has been the topic of several research analyst reports. Zacks Investment Research downgraded shares of vTv Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, May 4th. Canaccord Genuity reaffirmed a “buy” rating and issued a $15.00 price objective on shares of vTv Therapeutics in a report on Friday, August 19th.

The company’s 50 day moving average is $5.69 and its 200-day moving average is $5.77. The firm’s market cap is $51.16 million.

vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings results on Tuesday, August 16th. The company reported ($0.47) earnings per share (EPS) for the quarter. On average, analysts predict that vTv Therapeutics Inc. will post ($1.57) earnings per share for the current fiscal year.

vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.